Logo image
Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner
Journal article   Peer reviewed

Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner

K. Rünkorg, L. Orav, S. Kõks, T. Matsui, V. Volke and E. Vasar
Behavioural Brain Research, Vol.226(1), pp.335-339
2012
url
Link to Published Version *Subscription may be requiredView

Abstract

In this behavioural and pharmacological study in male CCK2 receptor-deficient mice (CCK2−/−), we evaluated the role of the interaction of endocannabinoids (eCBs) and cholecystokinin (CCK) on the regulation of anxiety-related and motor behaviours. Repeated treatment with amphetamine (2 mg/kg daily for four days) induced slightly weaker motor sensitisation in CCK2−/− mice compared to their wild-type (CCK2+/+) littermates. Co-administration of rimonabant (1 mg/kg) with amphetamine antagonised the development of motor sensitisation in CCK2+/+ mice. However, we did not find a similar effect of rimonabant in CCK2−/− mice. We did not find any differences between the behaviour of CCK2+/+ and CCK2−/− mice in models designed to assess emotional behaviours (dark/light exploration, marble burying and conditioned place aversion). This study supports the hypothesis that eCBs play a role in the development of amphetamine-induced sensitisation. Moreover, we have demonstrated that intact CCK2 receptors are necessary for the development of eCB-mediated sensitisation to amphetamine.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.195 Neuroendocrine & Intestinal Disorders
1.195.1096 Gastrin/CCK Functions
Web Of Science research areas
Behavioral Sciences
Neurosciences
ESI research areas
Neuroscience & Behavior
Logo image